中国P站

Recent advances in liquid biopsy are profoundly influencing cancer management, offering a minimally invasive alternative to traditional tissue biopsies. Techniques involving the analysis of circulating tumor DNA, circulating tumor cells, and extracellular vesicles are crucial for early detection, effective treatment monitoring, and the advancement of personalized medicine [1].

Extracellular vesicles, including exosomes and microvesicles, represent highly promising biomarkers for cancer diagnosis and prognosis. Their associated cargo, encompassing nucleic acids, proteins, and lipids, provides non-invasive avenues for early detection, accurate disease staging, and predicting patient response to various cancer therapies [2].

The integration of artificial intelligence and machine learning is transforming cancer biomarker discovery and validation, particularly with multi-omics data. AI methodologies are instrumental in deciphering complex genomic, proteomic, and metabolomic datasets, thereby improving diagnostic precision and facilitating tailored cancer treatment strategies [3].

Circulating tumor DNA holds significant potential for both early cancer detection and ongoing disease monitoring. Its utility spans non-invasive diagnosis, assessment of minimal residual disease, prediction of recurrence, and real-time tracking of treatment efficacy, poised to reshape existing cancer management paradigms [4].

Proteomics-based strategies are extensively employed for the discovery and validation of cancer biomarkers. Comprehensive reviews highlight various proteomic techniques, such as mass spectrometry, which enable the identification of specific proteins and their modifications in biological samples, leading to more precise diagnostics and targeted therapeutic interventions [5].

Epigenetic biomarkers, including DNA methylation, histone modifications, and non-coding RNAs, are critical in cancer research, progressing from basic investigation to clinical application. These indicators are vital for risk stratification, early detection, prognostication, and guiding therapeutic decisions in oncology [6].

Nanotechnology-based biosensors offer enhanced capabilities for detecting cancer biomarkers with improved sensitivity and specificity. The application of nanostructures in biosensing facilitates earlier and more accurate cancer diagnoses, particularly in point-of-care settings, representing a significant technological advancement [7].

Somatic mutations are increasingly recognized as crucial cancer biomarkers, central to the principles of precision oncology. Identification of these specific genetic alterations in tumor cells is pivotal for guiding personalized treatment selection, predicting drug responses, and diligently monitoring disease progression, ensuring more effective therapies [8].

Metabolomics plays a vital role in the discovery of cancer biomarkers by analyzing metabolic changes within biological samples. This comprehensive approach reveals unique metabolic signatures indicative of cancer, opening new avenues for early diagnosis, prognosis assessment, and a deeper understanding of disease mechanisms [9].

Biomarkers that predict response to immune checkpoint blockade therapy are essential for personalizing cancer immunotherapy. Factors such as PD-L1 expression, tumor mutational burden, and microsatellite instability are key in optimizing treatment strategies and ultimately improving patient outcomes in immunotherapy [10].

Description

The field of cancer management is being rapidly transformed by liquid biopsy, which provides a less invasive alternative to traditional methods. This technique focuses on analyzing circulating tumor DNA, circulating tumor cells, and extracellular vesicles to facilitate early detection, monitor treatment efficacy, and advance personalized medical approaches [1]. Extracellular vesicles, which comprise exosomes and microvesicles, are emerging as significant non-invasive biomarkers for cancer. Their internal cargo, consisting of nucleic acids, proteins, and lipids, shows great promise for enhancing early diagnosis, accurately staging disease, and predicting therapeutic responses across diverse cancer types [2]. The application of artificial intelligence and machine learning is fundamental in the rigorous process of discovering and validating cancer biomarkers, particularly through the utilization of multi-omics data. AI algorithms are designed to integrate complex genomic, proteomic, and metabolomic datasets, thereby significantly improving diagnostic accuracy and guiding individualized cancer treatment regimens [3]. Circulating tumor DNA is a focal point in current research for its capacity to enable early cancer detection and ongoing monitoring. This innovative biomarker is critical for non-invasive diagnostic procedures, assessing minimal residual disease, forecasting recurrence risk, and tracking the effectiveness of various treatments, thus revolutionizing cancer care [4]. Proteomics-based approaches are foundational for the identification and verification of cancer biomarkers. This involves employing sophisticated proteomic technologies, including advanced mass spectrometry, to detect specific proteins and their modifications in biological specimens. Such methods are pivotal in developing more precise cancer diagnostics and targeted therapies [5]. Epigenetic biomarkers, encompassing DNA methylation, histone modifications, and non-coding RNAs, are integral to cancer research, bridging basic science and clinical application. These biomarkers are invaluable for precise cancer risk stratification, ensuring early detection, determining prognosis, and informing strategic therapeutic interventions [6]. The development of nanotechnology-based biosensors offers a substantial improvement in the detection of cancer biomarkers. Nanostructures enhance the sensitivity and specificity of biomarker recognition, leading to more timely and accurate cancer diagnoses, especially in easily deployable point-of-care environments [7]. Somatic mutations are recognized as crucial cancer biomarkers, driving the evolution of precision oncology. Identifying unique genetic alterations within tumor cells is essential for tailored treatment selection, predicting individual drug responses, and meticulous monitoring of disease progression, resulting in significantly more personalized and effective therapeutic outcomes [8]. Metabolomics provides a powerful tool for discovering cancer biomarkers through the analysis of metabolic alterations in biological samples. This comprehensive approach uncovers distinct metabolic profiles associated with cancer, paving the way for advanced early diagnosis, refined prognostic assessments, and a deeper mechanistic understanding of the disease [9]. Identifying specific biomarkers is paramount for predicting patient responses to immune checkpoint blockade therapy in cancer. Evaluating factors such as PD-L1 expression, tumor mutational burden, and microsatellite instability is critical for individualizing immunotherapy strategies, thereby optimizing patient care and enhancing therapeutic success [10].

Conclusion

Recent advancements in cancer management are largely driven by innovative biomarker discovery and validation strategies. Liquid biopsy, leveraging circulating tumor DNA and extracellular vesicles, provides non-invasive methods for early detection, treatment monitoring, and personalized medicine. Artificial intelligence and multi-omics data integration are crucial for identifying novel biomarkers from complex genomic, proteomic, and metabolomic datasets. Proteomics, epigenetics, metabolomics, and the analysis of somatic mutations offer deep insights into cancer biology and enable precision oncology. Furthermore, nanotechnology-based biosensors enhance detection sensitivity, while specific biomarkers guide immune checkpoint blockade therapy, significantly improving patient outcomes. These integrated approaches are revolutionizing diagnostic accuracy, prognostic assessment, and therapeutic guidance, paving the way for more effective and individualized cancer care.

References

1. Alix TY, Rachel MP, S WK. (2024) .Mol Cancer 23:26.

   , ,

2. Xi W, Jingwei L, Xiangyu Z. (2023) .Front Oncol 13:1165037.

   , ,

3. Le Y, Chen H, Mengsha H. (2022) .Transl Oncol 22:101563.

   , ,

4. Ning L, Jia W, Yuzhe N. (2021) .Mol Ther Nucleic Acids 24:326-339.

   , ,

5. Chunhua Z, Hongmei L, Dongyan Z. (2021) .Cancers (Basel) 13:3276.

   , ,

6. Yuan Z, Xueshan L, Rongrong C. (2020) .Trends Genet 36:781-793.

   , ,

7. Jinhong C, Xiaoli Z, Qianming C. (2020) .ACS Sens 5:2715-2731.

   , ,

8. Chih-Rong S, Tzu-Chi C, Chien-Chang W. (2019) .Semin Cancer Biol 58:16-24.

   , ,

9. Yan L, Ruifeng L, Yongliang L. (2019) .Mol Cancer 18:144.

   , ,

10. Han L, Yaxin W, Qian G. (2020) .Mol Cancer 19:143.

    , ,